Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous disease in which management requires integration of clinical assessment, cardiovascular physiology, multimodality imaging, functional evaluation, and arrhythmic risk. This review examines contemporary evaluation, risk stratification, an...
A. Parodi, B. Baù, G. Piccolboni et al.· Journal of Clinical Medicine· 0 citations
Although current literature increasingly supports genotype-driven risk stratification in cardiomyopathies, a substantial proportion of patients remain gene-elusive despite comprehensive genetic testing. In this subgroup, clinical phenotype, prognosis, and arrhythmic risk are less clearly defined compared with gen...
M. Martini, L. Iezzi, A. Parodi et al.· European Heart Journal· 0 citations
BACKGROUND
Evidence of the diverse genetic architecture of dilated cardiomyopathy (DCM) continues to emerge and requires reassessment of the clinical relevance of implicated disease genes. Building on the 2019-2020 Clinical Genome Resource evaluation, the DCM gene curation expert panel reconvened in 2024-2025 to conduc...
E. Jordan, Phoenix L. Grover, P. Parker et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.